Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Hindsight>Brokers' Latest TPs/ Opinions on CHINA LIFE After Quarterly Results Ann
Recommend 41 Positive 59 Negative 22 |
||||
|
||||
|
Broker│ Rating│ Target Price (HKD) JPMorgan│Overweight│40 Morgan Stanley│Overweight│37.9 CLSA│Outperform│33 –> 37 Citi│Buy│36 Goldman Sachs│Neutral│28.5 Broker | Opinion JPMorgan | Strong growth in 1Q new business value offset the negative impact from lower profit, making the Company its sector top pick Morgan Stanley | 1Q new business value surged 76%, outpacing peers; business quality continued to improve CLSA | target price for CHINA LIFE (02628.HK)'s H-shares was lifted as 1Q new business value growth significantly beat expectations and far outpaced peers Citi│ 1Q results mixed, with outstanding new business value growth, although embedded value growth was slightly lower than that of PING AN (02318.HK) Goldman Sachs│1Q net profit growth beat expectations; new business value growth was robust Auto-translated by AI This article was automatically translated by AI, the original language version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
AASTOCKS Financial News |
||||
Copied to Clipboard
 |
||||
